Industry

Johnson & Johnson agrees to acquire Ollin Biosciences

The acquisition gives J&J OLN324, an investigational phase 3 drug being developed for wet age-related macular degeneration and diabetic macular edema.

Reported by 4 outlets Tuesday, November 17, 2026

Johnson & Johnson has agreed to acquire Ollin Biosciences, adding OLN324, an investigational bispecific antibody, to its pipeline. Healio reported that the phase 3 drug is being developed for wet age-related macular degeneration and diabetic macular edema. It targets VEGF and angiopoietin-2. BioPharma Dive reported that early study results supported the drug’s potential, while noting it would enter a crowded market.

Healio said J&J will pay $2.2 billion upfront, with an additional $1.125 billion in potential regulatory and commercial milestone payments. MedCity News described a $1.2 billion upfront payment and up to $1.1 billion in additional payments. Healio said the deal is expected to close before the end of the year. In a separate development funding agreement, Healio reported Blackstone Life Sciences will pay $750 million to J&J, while MedCity News said Blackstone agreed to pay up to $750 million.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.